Rezafungin (Rezzayo™), an intravenous once-weekly echinocandin that inhibits 1, 3-β-d-
glucan synthase, is being developed by Cidara Therapeutics. In March 2023, rezafungin …

Fungal infections are on the rise, driven by a growing population at risk and climate change.
Currently available antifungals include only five classes, and their utility and efficacy in …

Candida auris has been described as an emerging yeast species during the last decade. As
many as 25% of its strains may naturally exhibit multi-drug resistance to the currently …

The fungal pathogen Candida auris represents a severe threat to hospitalized patients. Its
resistance to multiple classes of antifungal drugs and ability to spread and resist …

Background Yet often overlooked in public health discourse, fungal infections pose a
crucialglobal disease burden associated with annual mortality rates approximately equal to …

The alarming spread and impact of multidrug-resistant Candida auris infections alongside
the limited therapeutic options have prompted the development of new antifungals. These …

Candida auris is an emerging, multidrug-resistant fungal pathogen that causes refractory
colonization and life-threatening, invasive nosocomial infections. The high proportion of C …

Introduction: Invasive fungal infection carries a high morbidity, mortality and economic cost.
In recent times, a rising incidence of fungal infection and antifungal resistance is occurring …

Invasive fungal infections caused by yeasts of the genus Candida carry high morbidity and
cause systemic infections with high mortality rate in both immunocompetent and …

Candida auris is emerging as a major global threat to human health. C. auris infections are
associated with high mortality due to intrinsic multi-drug resistance. Currently, therapeutic …